{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:00:31Z","timestamp":1784556031001,"version":"3.55.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,6,1]]},"DOI":"10.1001\/jamadermatol.2023.0784","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T15:33:57Z","timestamp":1682523237000},"page":"581","source":"Crossref","is-referenced-by-count":4,"title":["The Critical Need for Reliable and Clinically Meaningful Outcome Measures for Hidradenitis Suppurativa"],"prefix":"10.1001","volume":"159","author":[{"given":"Haley B.","family":"Naik","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"},{"name":"Associate Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"ded230005r1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/jamadermatol.2020.5467","article-title":"Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary.","volume":"157","author":"Frew","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ded230005r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6266","article-title":"Surgical procedural definitions for hidradenitis suppurativa developed by expert Delphi consensus.","author":"Bui","journal-title":"JAMA Dermatol"},{"issue":"2","key":"ded230005r3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/bjd.14475","article-title":"Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process.","volume":"175","author":"Ingram","year":"2016","journal-title":"Br J Dermatol"},{"key":"ded230005r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0797","article-title":"Validation of the Hidradenitis Suppurativa Investigator Global Assessment: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.","author":"Garg","journal-title":"JAMA Dermatol"},{"issue":"11","key":"ded230005r5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial.","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"6","key":"ded230005r6","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"issue":"6","key":"ded230005r7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.2016.30.issue-6","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"ded230005r8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa.","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"ded230005r9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/bjd.v181.3","article-title":"Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.","volume":"181","author":"Thorlacius","year":"2019","journal-title":"Br J Dermatol"},{"issue":"12","key":"ded230005r11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial.","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"issue":"2","key":"ded230005r12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.v37.2","article-title":"Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.","volume":"37","author":"Tzellos","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"ded230005r13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/bjd.v184.5","article-title":"Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment.","volume":"184","author":"Goldfarb","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"ded230005r14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014733","article-title":"Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes.","volume":"7","author":"Thorlacius","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"ded230005r15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/bjd.v187.2","article-title":"Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.","volume":"187","author":"Garg","year":"2022","journal-title":"Br J Dermatol"},{"key":"ded230005r10","unstructured":"InflaRx reports additional analysis of the SHINE phase IIb results for IFX-1 in hidradenitis suppurativa. 2019. Accessed March 19, 2023. https:\/\/www.inflarx.de\/Home\/Investors\/Press-Releases\/07-2019-InflaRx-Reports-Additional-Analysis-of-the-SHINE-Phase-IIb-Results-for-IFX-1-in-Hidradenitis-Suppurativa-.html"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2804251\/jamadermatology_naik_2023_ed_230005_1686855581.2086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T19:42:07Z","timestamp":1687376527000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2804251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.0784","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}